Research programme: adult stem cell therapies - Wellstat

Drug Profile

Research programme: adult stem cell therapies - Wellstat

Alternative Names: PN-951

Latest Information Update: 25 Nov 2015

Price : $50

At a glance

  • Originator Wellstat Therapeutics Corporation
  • Class Peptides
  • Mechanism of Action Stem cell modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Haematological disorders; Neurodegenerative disorders

Most Recent Events

  • 25 Nov 2015 Discontinued - Preclinical for Haematological disorders in USA (Parenteral)
  • 25 Nov 2015 Discontinued - Preclinical for Neurodegenerative disorders in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top